Pharmaceuticals policy

Global Cardiovascular Drugs Market Report 2020-2030: COVID-19 Impact and Recovery - ResearchAndMarkets.com

Wednesday, June 3, 2020 - 4:44pm

The "Cardiovascular Drugs Global Market Report 2020-30: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cardiovascular Drugs Global Market Report 2020-30: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering.
  • It places the market within the context of the wider cardiovascular drugs market, and compares it with other markets.
  • Asia-Pacific was the largest region in the global cardiovascular drugs market, accounting for 39% of the market in 2019.
  • It compares the cardiovascular drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast.

OpGen Expands Partnership with New York State Department of Health and IDC to Detect Antimicrobial-Resistant Infections

Wednesday, June 3, 2020 - 11:00am

The DOH, OpGen, IDC and all stakeholders will continue to work collaboratively to demonstrate that a sustainable, flexible infectious diseases reporting, tracking and surveillance tool for antimicrobial resistance can be applied across New York State.

Key Points: 
  • The DOH, OpGen, IDC and all stakeholders will continue to work collaboratively to demonstrate that a sustainable, flexible infectious diseases reporting, tracking and surveillance tool for antimicrobial resistance can be applied across New York State.
  • OpGen is providing its Acuitas AMR Gene Panel for rapid detection of multidrug-resistant bacterial pathogens along with its Acuitas Lighthouse Software for high resolution pathogen tracking.
  • The quick spread of antimicrobial resistant superbugs across our healthcare systems is lurking below the current medical crisis.
  • The Center serves a vital role in the New York State Department of Healths efforts to protect and promote the health of New Yorks citizens.

Lupin signs distribution agreements in key EU territories for orphan drug NaMuscla®

Wednesday, June 3, 2020 - 5:17am

Zug, Switzerland, 3 June: Lupin is pleased to announce that it has entered into distribution agreements with three companies for its orphan drug NaMuscla (mexiletine).

Key Points: 
  • Zug, Switzerland, 3 June: Lupin is pleased to announce that it has entered into distribution agreements with three companies for its orphan drug NaMuscla (mexiletine).
  • NaMuscla, which has been designated orphan drug status, received EU marketing authorization in December 2018.
  • These distribution agreements represent an important milestone for Lupin as we roll out commercialization of NaMuscla across Europe.
  • Collaborating with partners that are highly effective in their focus territories ensures patients will receive the drug in as effective manner as possible, said Thierry Volle, President EMEA, Lupin.

James E. Wagner Announces Court Approval of Sale of Assets

Tuesday, June 2, 2020 - 4:40pm

The closing of the Transaction is currently set to occur on or before June 30, 2020, provided that all remaining conditions are satisfied.

Key Points: 
  • The closing of the Transaction is currently set to occur on or before June 30, 2020, provided that all remaining conditions are satisfied.
  • Readers are urged to consult the full text of all documents available on SEDAR and the Monitor's website for further, more detailed, information.
  • James E. Wagner Cultivation Corporation's wholly owned subsidiary is a Licensed Producer under the Cannabis Regulations, formerly theAccess to Cannabis for Medical Purposes Regulations("ACMPR").
  • JWC is a premium cannabis brand, focusing on producing clean, consistent cannabis using an advanced and proprietary aeroponic platform named GrowthSTORM.

Global Commercial Aircraft Market to Focus on Innovative Digital Solutions and Leasing Post-COVID-19, Says Frost & Sullivan

Tuesday, June 2, 2020 - 3:04pm

However, the aspirational forecast scenario reflects a faster rebound, estimating that the market could hit $411.63 billion by 2025, at a compound annual growth rate (CAGR) of 6.2%.

Key Points: 
  • However, the aspirational forecast scenario reflects a faster rebound, estimating that the market could hit $411.63 billion by 2025, at a compound annual growth rate (CAGR) of 6.2%.
  • For further information on this analysis, please visit: http://frost.ly/454
    "The COVID-19 pandemic has swept the globe, impacting every industry in every country.
  • Few other industries have been disrupted to the magnitude of the global commercial aerospace market," said Timothy Kuder, Aerospace & Defense Industry Analyst at Frost & Sullivan.
  • Market players can leverage emerging digital technologies such as blockchain to help comply with regulator-mandated traceability requirements of many aerospace digital services.

Tigermed Lauded by Frost & Sullivan for Its Rapid, Large-Scale Clinical Developmental Services

Tuesday, June 2, 2020 - 3:00pm

LONDON, June 2, 2020 /PRNewswire/ --Based on its recent analysis of the Chinese contract research organizations (CROs) market, Frost & Sullivan recognizes Tigermed with the 2020 Chinese Customer Value Leadership Awardfor its full clinical developmental services.

Key Points: 
  • LONDON, June 2, 2020 /PRNewswire/ --Based on its recent analysis of the Chinese contract research organizations (CROs) market, Frost & Sullivan recognizes Tigermed with the 2020 Chinese Customer Value Leadership Awardfor its full clinical developmental services.
  • Tigermed's clinical trial services include regulatory affairs, biometrics, clinical operations and data management, and post-marketing studies.
  • Additionally, its host of value-added clinical services cover areas such as imaging, pharmacovigilance, and central laboratory services..
  • "We are honored to be recognized by Frost & Sullivan," said Xiaochun Cao, Co-founder, Executive Director and General Manager of Tigermed.

Tigermed Lauded by Frost & Sullivan for Its Rapid, Large-Scale Clinical Developmental Services

Tuesday, June 2, 2020 - 3:00pm

LONDON, June 2, 2020 /PRNewswire/ --Based on its recent analysis of the Chinese contract research organizations (CROs) market, Frost & Sullivan recognizes Tigermed with the 2020 Chinese Customer Value Leadership Awardfor its full clinical developmental services.

Key Points: 
  • LONDON, June 2, 2020 /PRNewswire/ --Based on its recent analysis of the Chinese contract research organizations (CROs) market, Frost & Sullivan recognizes Tigermed with the 2020 Chinese Customer Value Leadership Awardfor its full clinical developmental services.
  • Tigermed's clinical trial services include regulatory affairs, biometrics, clinical operations and data management, and post-marketing studies.
  • Additionally, its host of value-added clinical services cover areas such as imaging, pharmacovigilance, and central laboratory services..
  • "We are honored to be recognized by Frost & Sullivan," said Xiaochun Cao, Co-founder, Executive Director and General Manager of Tigermed.

Global Commercial Aircraft Market to Focus on Innovative Digital Solutions and Leasing Post-COVID-19, Says Frost & Sullivan

Tuesday, June 2, 2020 - 2:27pm

However, the aspirational forecast scenario reflects a faster rebound, estimating that the market could hit $411.63 billion by 2025, at a compound annual growth rate (CAGR) of 6.2%.

Key Points: 
  • However, the aspirational forecast scenario reflects a faster rebound, estimating that the market could hit $411.63 billion by 2025, at a compound annual growth rate (CAGR) of 6.2%.
  • For further information on this analysis, please visit: http://frost.ly/454
    "The COVID-19 pandemic has swept the globe, impacting every industry in every country.
  • Few other industries have been disrupted to the magnitude of the global commercial aerospace market," said Timothy Kuder, Aerospace & Defense Industry Analyst at Frost & Sullivan.
  • Market players can leverage emerging digital technologies such as blockchain to help comply with regulator-mandated traceability requirements of many aerospace digital services.

EAS COVID-19 Reopening Strategies - Are you Prepared?

Tuesday, June 2, 2020 - 1:38pm

Have you updated your facility and staff hygiene operations, and were Good Manufacturing Practices (GMPs) change controls incorporated?

Key Points: 
  • Have you updated your facility and staff hygiene operations, and were Good Manufacturing Practices (GMPs) change controls incorporated?
  • There are numerous challenges to reopening, regrouping and ensuring you compliance with federal and state regulations are in order.
  • EAS Consulting Group along with our parent organization, Certified Laboratories , offers remote assistance for all these challenges and more.
  • Contact EAS today to understand your regulatory requirements and learn how we can be of assistance.

Leading Drug Innovator Reorganizes Into Two Separate Companies

Tuesday, June 2, 2020 - 1:31pm

The new company is led by President and CEO William Moore, PhD, who previously ran Vizuri Health Sciences and its prescription drug development efforts.

Key Points: 
  • The new company is led by President and CEO William Moore, PhD, who previously ran Vizuri Health Sciences and its prescription drug development efforts.
  • "The split of Vizuri Health Sciences into two separate companies enables us to ardently focus on these market opportunities."
  • Current Vizuri board chairman, John P. Walker, a highly successful serial entrepreneur, will lead the boards of both companies.
  • "This move will allow both companies to focus on their key strengths and to return higher value to shareholders."